Spots Global Cancer Trial Database for solid tumor cancer
Every month we try and update this database with for solid tumor cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Meaning-Centered Pain Coping Skills Training | NCT04431830 | Advanced Solid ... Pain | Meaning-Centere... | 18 Years - | Duke University | |
| Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors | NCT04354064 | Healthy Volunte... Prostate Cancer Head and Neck C... Esophageal Canc... Genitourinary C... Sarcoma Breast Cancer Colon Cancer Gastrointestina... Solid Tumor Can... Lung Cancer Skin Cancer Melanoma | 18 Years - | Washington University School of Medicine | ||
| A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors | NCT00046111 | Lung Cancer, Sm... Solid Tumor Can... | topotecan | 18 Years - | GlaxoSmithKline | |
| Ispinesib In Combination With Capecitabine In Patients With Solid Tumors | NCT00119171 | Solid Tumor Can... | Ispinesib Capecitabine | 18 Years - | GlaxoSmithKline | |
| A Retrospective Immunohistochemistry Study of the Expression of Glycine/ Serine Pathway Molecules in Solid Tumors | NCT02103920 | Solid Tumor Can... | 21 Years - | National University Hospital, Singapore | ||
| Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients | NCT01309490 | Malignant Solid... | Ribavirin | 18 Years - | Jewish General Hospital | |
| Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer | NCT01215500 | Tumor Cancer Melanoma Sarcoma Carcinoma | Hypofractionate... | 18 Years - | University of Chicago | |
| Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas | NCT00085904 | Solid Tumor Can... Lymphoma | SB-485232 | 18 Years - | GlaxoSmithKline | |
| Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors | NCT00085878 | Solid Tumor Can... | SB-485232 | 18 Years - | GlaxoSmithKline | |
| A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy | NCT00891761 | Cancer Chemotherapy-In... Nausea and Vomi... Solid Tumor Can... | Dexamethasone Dexamethasone IV casopitant (... IV casopitant (... Ondansetron | 18 Years - | GlaxoSmithKline | |
| Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas | NCT00085904 | Solid Tumor Can... Lymphoma | SB-485232 | 18 Years - | GlaxoSmithKline | |
| SB-715992 In Combination With Docetaxel In Patients With Solid Tumors | NCT00169520 | Solid Tumor Can... | docetaxel SB-715992 | 18 Years - | GlaxoSmithKline | |
| SB-743921 In Patients With Solid Tumors | NCT00136513 | Solid Tumor Can... | SB-743921 | 18 Years - | GlaxoSmithKline | |
| Trial of Written Exposure for Metastatic Cancer Patients (EASE) | NCT06042400 | Metastatic Canc... Solid Tumor Can... Lymphoprolifera... Anxiety Post-traumatic ... Fear of Cancer ... | Written Exposur... | 18 Years - | University of Colorado, Boulder | |
| A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy | NCT00891761 | Cancer Chemotherapy-In... Nausea and Vomi... Solid Tumor Can... | Dexamethasone Dexamethasone IV casopitant (... IV casopitant (... Ondansetron | 18 Years - | GlaxoSmithKline | |
| Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients | NCT01309490 | Malignant Solid... | Ribavirin | 18 Years - | Jewish General Hospital | |
| Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas | NCT00085904 | Solid Tumor Can... Lymphoma | SB-485232 | 18 Years - | GlaxoSmithKline |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
